These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 18499100

  • 1. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.
    Eur J Pharmacol; 2008 Jul 07; 588(2-3):325-32. PubMed ID: 18499100
    [Abstract] [Full Text] [Related]

  • 2. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.
    Eur J Pharmacol; 2009 Jan 14; 602(2-3):448-54. PubMed ID: 19038243
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):306-14. PubMed ID: 18538760
    [Abstract] [Full Text] [Related]

  • 5. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.
    J Pharmacol Exp Ther; 2006 Aug 28; 318(2):914-21. PubMed ID: 16648370
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.
    Clin Ther; 2006 Jan 28; 28(1):55-72. PubMed ID: 16490580
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N, McClean PL, Flatt PR.
    J Pept Sci; 2007 Jun 28; 13(6):400-5. PubMed ID: 17486662
    [Abstract] [Full Text] [Related]

  • 9. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
    Ahrén B, Winzell MS, Wierup N, Sundler F, Burkey B, Hughes TE.
    Regul Pept; 2007 Oct 04; 143(1-3):97-103. PubMed ID: 17482289
    [Abstract] [Full Text] [Related]

  • 10. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
    Havale SH, Pal M.
    Bioorg Med Chem; 2009 Mar 01; 17(5):1783-802. PubMed ID: 19217790
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Shiraki K, Hayakawa M, Shibasaki M.
    Metabolism; 2009 Mar 01; 58(3):379-86. PubMed ID: 19217455
    [Abstract] [Full Text] [Related]

  • 18. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK.
    Ann Pharmacother; 2007 Jan 01; 41(1):51-60. PubMed ID: 17190843
    [Abstract] [Full Text] [Related]

  • 19. Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.
    Zhang X, Wang Z, Huang Y, Wang J.
    Diabetes Obes Metab; 2011 Apr 01; 13(4):337-47. PubMed ID: 21205126
    [Abstract] [Full Text] [Related]

  • 20. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF.
    Curr Opin Investig Drugs; 2008 Apr 01; 9(4):402-13. PubMed ID: 18393107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.